In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Freedom And Capital Drive Intarcia Down Independent Path

Executive Summary

With a lucrative and unique royalty financing deal and positive first results from its global Phase III diabetes study, Intarcia has emerged as one of the biotech industry’s most valuable private companies and is in position to control its own destiny. It just may disrupt the type 2 diabetes market in the process.

Advertisement

Related Content

Investors Boost Metabolic Companies
Dominating Diabetes Deals
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch on in a Big Way

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel